— Clovis Oncology (NASDAQ: CLVS) reported a fourth-quarter 2019 loss of $1.81 per share versus a loss of $1.71 per share expected.
— Product revenues grew by 30% to $39.3 million versus $38.97 million expected. The top line was driven by an increase in the US net product revenue.
— The supply of free drugs distributed to eligible patients in the U.S. through the Rubraca patient assistance program for Q4 2019 was 18% of the overall US commercial supply, compared to 26% reported in Q4 2018.
— Research and development expenses increased by 2% year-over-year due primarily to higher research and development costs for rucaparib clinical trials.
— The company believes it has sufficient cash, cash equivalents, and available-for-sale securities to fund its operating plan into the second half of 2021. This is based on anticipated revenue, spending, available financing sources, and existing cash.
Most Popular
DG Earnings: All you need to know about Dollar General’s Q1 2023 earnings results
Dollar General Corporation (NYSE: DG) reported its first quarter 2023 earnings results today. Net sales increased 6.8% year-over-year to $9.3 billion, driven mainly by positive sales contributions from new stores and
HRL Earnings: Key highlights from Hormel Foods’ Q2 2023 financial results
Hormel Foods Corporation (NYSE: HRL) reported second quarter 2023 earnings results today. Net sales of $3 billion were down 3.8% year-over-year. Net earnings attributable to Hormel Foods Corporation were $217.2
Everything you need to know about Salesforce’s Q1 2024 financial results
Customer relationship management platform Salesforce, Inc. (NYSE: CRM) on Wednesday reported an increase in first-quarter adjusted earnings, aided by strong revenue growth. First-quarter profit, excluding non-recurring items, increased to $1.69
